Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 497-516 , December 2007

Incretin hormone mimetics and analogues in diabetes therapeutics

  • Brian D. Green (Lecturer)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 2890 976541; Fax: +44 2890 976513.

References 

  1. Elrick H, Stimmler L, Hlad CJ, et al. Plasma insulin response to oral and intravenous glucose administration. The Journal of Clinical Endocrinology and Metabolism. 1964;24:1076–1082
  2. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. The Journal of Clinical Investigation. 1967;46:1954–1962
  3. Unger RH, Eisentraut AM. Entero-insular axis. Archives of Internal Medicine. 1969;123:261–266
  4. Creutzfeldt M. Candidate hormones of the gut. XV. Insulin-releasing factors of the gastrointestinal mucosa (Incretin). Gastroenterology. 1974;67:748–750
  5. Orskov C, Rabenhoj L, Wettergren A, et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43:535–539
  6. Gallwitz B, Witt M, Morys-Wortmann C, et al. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1. Regulatory Peptides. 1996;63:17–22
  7. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157
  8. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053
  9. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52
  10. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type-2-diabetic patients. Diabetes. 2001;50:609–613
  11. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of Clinical Investigation. 1993;91(1):301–307
  12. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regulatory Peptides. 1994;51:63–74
  13. Hargrove DM, Nardone NA, Persson LM, et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism. 1995;44:1231–1237
  14. Andersen DK, Elahi D, Brown JC, et al. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. The Journal of Clinical Investigation. 1978;62:152–161
  15. Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care. 1996;19:580–586
  16. Valverde I, Morales M, Clemente F, et al. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Letters. 1994;349:313–316
  17. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, et al. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia. 1994;37:1163–1166
  18. O'Harte FP, Gray AM, Abdel-Wahab YH, et al. Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle. Peptides. 1997;18:1327–1333
  19. Elahi D, Meneilly GS, Minaker KL, Rowe JW, et al. Regulation of hepatic glucose production by gastric inhibitory polypeptide in man. Canadian Journal of Physiology and Pharmacology. 1986;65:18
  20. O'Harte FP, Abdel-Wahab YH, Conlon JM, et al. Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochimica et Biophysica Acta. 1998;1425:319–327
  21. Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiologica Scandinavica. 1997;160:413–422
  22. Rudovich NN, Rochlitz HJ, Pfeiffer AF. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type-2-diabetic patients. Diabetes. 2004;53:2359–2365
  23. Ahren B, Thomaseth K, Pacini G. Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Diabetologia. 2005;48:2140–2146
  24. Maxwell V, Shulkes A, Brown JC, et al. Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man. Digestive Diseases and Sciences. 1980;25:113–116
  25. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Ameriacn Journal of Physiology. Regulatory, Integrative and Comparitive Physiology. 2005;288:R1695–R1706
  26. Little TJ, Pilichiewicz AN, Russo A, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. The Journal of Clinical Endocrinology and Metabolism. 2006;91:1916–1923
  27. Horowitz M, Nauck M. To be or not to be – an incretin or enterogastrone?. Gut. 2006;55:148–150
  28. Madsbad S, Schmitz O, Ranstam J, et al. NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type-2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27:1335–1342
  29. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type-2 diabetes. Diabetes Care. 2005;28:1092–1100
  30. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type-2 diabetes: a randomized trial. Annals of Internal Medicine. 2007;146:477–485
  31. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type-2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–1091
  32. Kim JG, Baggio LL, Bridon DP, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes. 2003;52:751–759
  33. Flint A, Raben A, Rehfeld JF, et al. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. International Journal of Obesity and Related Metabolic Disorders. 2000;24:288–298
  34. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69–72
  35. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology. 2003;144:5145–5148
  36. Buteau J, Foisy S, Joly E, et al. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52:124–132
  37. Green BD, Lavery KS, Irwin N, et al. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. The Journal of Pharmacology and Experimaental Therapeutics. 2006;318:914–921
  38. Stoffers DA. The development of beta-cell mass: recent progress and potential role of GLP-1. Hormone and Metabolic Research. 2004;36:811–821
  39. Kim SJ, Winter K, Nian C, et al. Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. The Journal of Biological Chemistry. 2005;280:22297–22307
  40. Ehses JA, Casilla VR, Doty T, et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology. 2003;144:4433–4445
  41. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. The Journal of Endocrinology. 2002;174:233–246
  42. Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metabolism. 2006;4:391–406
  43. Couto FM, Minn AH, Pise-Masison CA, et al. Exenatide blocks JAK1-STAT1 in pancreatic beta cells. Metabolism. 2007;56:915–918
  44. Marenah L, McCluskey JT, Abdel-Wahab YH, et al. A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones. Biological Chemistry. 2006;387:941–947
  45. Rickels MR, Mueller R, Markmann JF, et al. Effect of GLP-1 on beta- and alpha-cell function during glucose potentiated arginine testing in islet transplant recipients: preliminary results. Diabetes. 2006;55(S1):A60
  46. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clinical Science (London). 2005;108:277–292
  47. Green BD, Flatt PR, Bailey CJ. Inhibition of dipeptidylpeptidase IV activity as a therapy of type-2 diabetes. Expert Opinion on Emerging Drugs. 2006;11:525–539
  48. Deacon CF. Circulation and degradation of GIP and GLP-1. Hormone and Metabolic Research. 2004;36:761–765
  49. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. European Journal of Pharmacology. 1996;318:429–435
  50. Deacon CF, Plamboeck A, Moller S, et al. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. American Journal of Physiology. Endocrinology and Metabolism. 2002;282:E873–E879
  51. Green BD, Mooney MH, Gault VA, et al. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). Metabolism. 2004;53:252–259
  52. Deacon CF, Plamboeck A, Rosenkilde MM, et al. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. American Journal of Physiology. Endocrinology and Metabolism. 2006;291:E468–E475
  53. Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP-4) inhibitors: A newly emerging drug class for the treatment of type-2 diabetes. Diabetes & Vascular Disease Research. 2006;3:159–165
  54. Drucker DJ. The role of gut hormones in glucose homeostasis. The Journal of Clinical Investigation. 2007;117:24–32
  55. Green BD, Gault VA, O'Harte FPM, et al. Structurally modified analogues of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Current Pharmaceutical Design. 2004;10:3651–3662
  56. O'Harte FPM, Gault VA, Parker JC, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002;45:1281–1291
  57. Gault VA, Hunter K, Irwin N, et al. Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists. Archives of Biochemistry and Biophysics. 2007;461:263–274
  58. O'Harte FPM, Hunter K, Gault VA, et al. Antagonistic effects of two novel GIP analogues, (Hyp3)GIP and (Hyp3)GIPLys16PAL on the biological actions of GIP and longer term effects in diabetic ob/ob mice. The American Journal of Physiology. 2007;292:E1674–E1682
  59. Irwin N, Green BD, Mooney M, et al. A novel long-acting agonist of glucose-dependent insulinotropic polypeptide (GIP) suitable for once daily administration in type-2 diabetes. The Journal of Pharmacology and Experimental Therapeutics. 2005;314:1187–1194
  60. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia. 2006;49:253–260
  61. Chou JZ, Place GD, Waters DG, et al. A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics. Journal of Pharmaceutical Sciences. 1997;86:768–773
  62. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. American Journal of Physiology. Endocrinology and Metabolism. 2002;283:E745–E752
  63. Irwin N, Green BD, Gault VA, et al. Degradation, insulin secretion and antihyperglycaemic actions of two palmitate-derivatized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide (GIP). Journal of Medicinal Chemistry. 2005;48:1244–1250
  64. Irwin N, Gault VA, Green BD, et al. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Biological Chemistry. 2005;386:679–687
  65. Irwin N, O'Harte FPM, Gault VA, et al. Development and characterization of novel long-acting fatty acid derivatised analogs of glucose-dependent insulinotropic polypeptide (GIP) with improved antidiabetic potential. Journal of Medicinal Chemistry. 2006;49:1047–1054
  66. Salhanick AI, Clairmont KB, Buckholz TM, et al. Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide. Bioorganic & Medicinal Chemistry Letters. 2005;15:4114–4117
  67. Lee S, Youn YS, Lee SH, et al. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia. 2006;49:1608–1611
  68. Youn YS, Chae SY, Lee S, et al. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochemical Pharmacology. 2007;73:84–93
  69. Giannoukakis N. CJC-1131. ConjuChem. Current Opinion in Investigational Drugs. 2003;4:1245–1249
  70. Leger R, Thibaudeau K, Robitaille M, et al. Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorganic & Medicinal Chemistry Letters. 2004;14:4395–4398
  71. Baggio LL, Huang Q, Brown TJ, et al. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004;53:2492–2500
  72. Chen D, Liao J, Li N, et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:943–948
  73. Knudsen LB, Kiel D, Teng M, et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Sciences of the United States of America. 2007 Jan 16;104(3):937–942
  74. Pan CQ, Buxton JM, Yung SL, et al. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. Journal of Biological Chemistry. 2006;281:12506–12515
  75. Claus TH, Pan CQ, Buxton JM, et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type-2 diabetes. Journal of Endocrinology. 2007;192:371–380
  76. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type-2 diabetes. Diabetes Care. 2003;26:2370–2377
  77. Buse JB, Henry RR, Han J, et al. Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type-2 diabetes. Diabetes Care. 2004;27:2628–2635
  78. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type-2 diabetes. Diabetes. 2004;53:1187–1194
  79. Harder H, Nielsen L, Tu DT, et al. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type-2 diabetes. Diabetes Care. 2004;27:1915–1921
  80. Nauck MA, Hompesch M, Filipczak R, et al. NN2211-1499 Study Group Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type-2 diabetes. Experimental and Clinical Endocrinology & Diabetes. 2006;114:417–423
  81. Feinglos MN, Saad MF, Pi-Sunyer FX, et al. Liraglutide Dose-Response Study Group Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type-2 diabetes. Diabetic Medicine. 2005;22:1016–1023
  82. Kapitza C, Trautmann ME, Heise T, et al. Daily administration of LY307161 SR (GLP-1) analog normalizes blood glucose in type-2 diabetes. Diabetes. 2002;51(S2):A84
  83. Gault VA, Flatt PR, O'Harte FPM. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential. Neuropeptides. 2003;37:253–263
  84. Meier JJ, Gallwitz B, Kask B, et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type-2 diabetes and healthy control subjects. Diabetes. 2004;53:S220–S224
  85. Meier JJ, Nauck MA, Siepmann N, et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection t euglycaemia in first-degree relatives of patients with type-2 diabetes and control subjects. Metabolism. 2003;52:1579–1585
  86. Meneilly GS, Bryer-Ash M, Elahi D. The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care. 1993;16:110–114
  87. Aaboe K, Knop FK, Vilsboll T, et al. Acute administration of a sulphonylureas compound restores the insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type-2 diabetes. Diabetologia. 2007;50(supplement 1):S248–S249
  88. Hojberg PV, Vilsboll T, Bache M, et al. Four weeks of near-normalization of blood glucose restores the insulin response to GIP and improves the insulin response to GLP-1 in patients with type-2 diabetes. Diabetologia. 2007;50(supplement 1):S111
  89. Lynn FC, Pamir N, Ng EH, et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes. 2001;50:1004–1011
  90. Gedulin B, Hargrave D, Smith P, et al. Insulinotropic actions of a long-acting GIP analo AC163794 in vivo. Diabetes. 2006;56(S1):A380
  91. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sciences. 2000;66:91–103
  92. Yamada Y, Miyawaki K, Tsukiyama K, et al. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes. 2006;55:S86–S91
  93. Gault VA, Irwin N, Green BD, et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalitities of islet structure in obestity-diabetes. Diabetes. 2005;54:2436–2446
  94. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Medicine. 2002;8:738–742
  95. Hansotia T, Maida A, Flock G, et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight and energy expenditure. The Journal of Clinical Investigation. 2007;117:143–152
  96. Gault VA, McClean PL, Cassidy RC, et al. Chemical GIP receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high fat and cafeteria diets. Diabetologia. 2007;50:1752–1762
  97. Irwin N, McClean PL, O'Harte FPM, et al. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist, (Pro3)GIP, prevents the development of diabetes and related metabolic abnormalities associated with genetically-inherited obesity in ob/ob mice. Diabetologia. 2007;50:1532–1540
  98. Zhou H, Yamada Y, Tsukiyama K, et al. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochemical and Biophysical Research Communications. 2005;335:937–942
  99. Gault VA, O'Harte FPM, Harriott P, et al. Characterisation of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochemical and Biophysical Research Communications. 2002;290:1420–1426
  100. Flatt PR. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?. Diabetes & Vascular Disease Research. 2007;4:151–153
  101. Clements RH, Gonzalez QH, Long CI, et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type II diabetes mellitus. The American Surgeon. 2004;70:1–5
  102. Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type-2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55:2025–2031
  103. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type-2 diabetes. Lancet. 2006;368:1696–1705
  104. Green BD, Flatt PR, Bailey CJ. Development and therapeutic potential of incretin hormone analogues for type-2 diabetes. The British Journal of Diabetes and Vascular Diseases. 2005;5:134–140
  105. Irwin N, Clarke G, Green BD, et al. Evaluation of the antidiabetic activity of DPP-IV resistant N-terminally-modified versus mid-chain acylated analogues of glucose-dependendent insulinotropic polypeptide. Biochemical Pharmacology. 2006;72:719–728
  106. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type-2 diabetes. Diabetes Care. 2007;30:1608–1610
  107. Huang J, Sakamuri S, Leedom T, et al. CVX-73: a GLP-1 mimetic CovX-Body with potent incretin bioactivity and extended pharmacokinetics in rodent and non-human primate. Diabetes. 2007;56(S1):A141

PII: S1521-690X(07)00086-3

doi: 10.1016/j.beem.2007.09.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 497-516 , December 2007

Article Tools

* Image Usage & Resolution